GYRE (Gyre Therapeutics) Moat Score: 3/10 (As of Jul. 01, 2026)


GYRE Gyre Therapeutics Inc GYRE
39 GF Score
Price $6.59
GF Value $9.82
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is Gyre Therapeutics Moat Score?

Gyre Therapeutics GYRE +2.01% 39 Moat Score is 3 as of Jul. 01, 2026. GuruFocus rates GYRE with a GF Score™ of 39/100 and a GF Value™ of $9.82 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 1,400 Biotechnology companies, Gyre Therapeutics ranks better than 75.5% on this metric.

Gyre Therapeutics has the Moat Score of 3, which implies that the company might have No Moat - Very weak/transient advantages.

Gyre Therapeutics has No Moat: Gyre Therapeutics Inc has some intellectual property but lacks significant market share, customer switching costs, or regulatory barriers. Its competitive advantages are weak and transient, limiting its moat.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Gyre Therapeutics might have No Moat - Very weak/transient advantages.

Gyre Therapeutics  (NAS:GYRE) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Gyre Therapeutics Moat Score Related Terms

GYRE vs RLMD, ACRS, SGP: Moat Score Comparison

For the Biotechnology subindustry, Gyre Therapeutics's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Gyre Therapeutics Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Gyre Therapeutics's Moat Score distribution charts can be found below:

* The bar in red indicates where Gyre Therapeutics's Moat Score falls into.


GYRE
39GF Score
Gyre Therapeutics Inc GYRE
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 3 mean?
Gyre Therapeutics (GYRE) has a Moat Score of 3 as of Jul. 01, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Gyre Therapeutics ranks #343 out of 1400 companies in the Biotechnology industry, placing it in the top 24.5%.
Is Gyre Therapeutics' Moat Score too high?
Gyre Therapeutics' current Moat Score is 3. The Biotechnology industry median Moat Score is 2.00. Gyre Therapeutics' value of 3 is 50% above this industry median. Based on the distribution chart, Gyre Therapeutics ranks #343 out of 1400 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Gyre Therapeutics has a GF Score™ of 39/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Gyre Therapeutics' Moat Score compare to RLMD and ACRS?
According to the Biotechnology industry distribution chart, Gyre Therapeutics ranks #343 out of 1400 companies for Moat Score. This places Gyre Therapeutics in the top 25% of its industry — outperforming the majority of peers. The industry median Moat Score is 2.00. Gyre Therapeutics' value of 3 is 50% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,400 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Gyre Therapeutics's current Moat Score of 3 is 50% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Gyre Therapeutics's current Moat Score is 3. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gyre Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Gyre Therapeutics (GYRE) is currently considered Significantly Undervalued. The stock's GF Value™ is $9.82, compared to a current price of $6.59 — trading 32.9% below its estimated fair value. The current Moat Score is 3 and 50% above the Biotechnology industry median of 2.00. Gyre Therapeutics' overall GF Score™ is 39/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Gyre Therapeutics (GYRE), the current Moat Score is 3 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Gyre Therapeutics (GYRE) Overvalued in 2026?

Based on GuruFocus' analysis, Gyre Therapeutics stock appears to be undervalued. The current stock price of $6.59 is trading 32.9% below its estimated GF Value™ of $9.82. GuruFocus considers Gyre Therapeutics to be Significantly Undervalued.

Key valuation signals for GYRE:

  • Moat Score: 3
  • GF Value™: $9.82 vs. price of $6.59 (32.9% below fair value)
  • GF Score™: 39/100 with 2 warning signs
  • Industry Position: 50% above the Biotechnology median (#343 of 1400)

No single metric tells the full story. See the GYRE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Gyre Therapeutics Business Description

Other Exchanges L9S:Germany
Address 12770 High Bluff Drive, Suite 150, San Diego, CA, USA, 92130
Gyre Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of small-molecule therapies for the treatment of organ fibrosis and inflammatory diseases. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.
39GF Score

Get the complete analysis for GYRE

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$6.59
Price
$9.82
GF Value